Conflicts of interest involving public policy
Press Conference prior to the 2006 FDA Advisory Committee Public Hearing on the connection between antidepressants and suicidal thoughts and actions. The press conference was put together by the family of Woody Witczak. Vera Sharav: Watch on Youtube Kim Witczak: Watch on youtube Dr. Joseph Glenmullen discussed a side effect…
FDA Advisory Panel & CDC Director are Complicit in Sacrificing Children’s Lives to Protect Pfizer from Liability On October 19th and 20th, 2022 ACIP, Advisory Committee on Immunization Practices, met and voted unanimously to add the experimental covid “vaccine” to the list of CDC recommended vaccines for children. The ACIP panel…
America’s health care expenditure is about to go through the roof–without improving anyone’s health!
Dr. Joshua Sharfstein, the FDA’s principal deputy commissioner, acknowledged: “The message here is that there were problems with the integrity of F.D.A.’s decision-making process that have solutions.”
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
The FDA is sliding rapidly down the slippery slope, abandoning widely accepted, international ethical research standards articulated in the internationally accepted, Declaration of Helsinki–to facilitate commercial medical experiments.
FDA officials who continue to run its powerful center for drug evaluation (CDER) have once again shown bad faith by appointing financially compromised doctors to the Psychopharmacologic Drugs Advisory Committee (PDAC) advisory panel.
Dr. Margaret "Peggy" Hamburg, a former health commissioner in New York City, is the leading candidate to become FDA commissioner, the agency's top job, while Baltimore health chief Joshua Sharfstein is in line to become a deputy commissioner
The Washington Post suggests, the chance for success in overhauling US healthcare depends on President Obama's ability to keep the major–discordant–players on board.
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
Dr. Diane M. Harper, a lead researcher in the development of the humanpapilloma virus vaccine, who says giving the drug to 11-year-old girls "is a great big public health experiment."
